benefitscanada.com·há cerca de 1 mês Approval of weight loss drug for sleep apnea could create financial risk for plan sponsors: expert
Health Canada’s recent approval of weight loss drug Zepbound as a treatment for obstructive sleep apnea in obese adults could create financial risks for benefits plan sponsors, says Joseph Koo,